Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Men and women aged 18 through 60 years inclusive

• Schizophrenia diagnosis

• Body Mass Index (BMI) 20-27 kg/m2 (inclusive)

• Provision of written informed consent before initiation of any study

Exclusion Criteria:

• AIDS & hepatitis B

• History of seizure disorder

• History of episodic,idiopathic orthostatic hypotension